Together, these findings suggest that there is a considerable subgroup of autism spectrum disorders of unknown etiology with defects in PI3K/mTOR signaling, which could qualify for a therapeutic strategy targeted at this pathway. This evidence concerns the gene PIK3CD and autism spectrum disorder.